Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, http://dx.doi.org/10.1111/anae.16068
Journal articles | 2023
Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2023, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16203
Journal articles | 2022
Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117
Journal articles | 2022
Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727
Journal articles | 2021
Milder T; Stocker S; Baysari M; Day RO; Greenfield J, 2021, 'Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', DIABETES, 70, http://dx.doi.org/10.2337/db21-779-P
Journal articles | 2021
Milder TY; Stocker SL; Baysari M; Day RO; Greenfield JR, 2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, 180, pp. 109036, http://dx.doi.org/10.1016/j.diabres.2021.109036
Journal articles | 2020
Milder TY; Day RO; Stocker SL; Greenfield JR, 2020, 'Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes', Internal Medicine Journal, 50, pp. 645 - 646, http://dx.doi.org/10.1111/imj.14819
Journal articles | 2020
Milder TY; Stocker SL; Day RO; Greenfield JR, 2020, 'Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease', Drug Safety, 43, pp. 1211 - 1221, http://dx.doi.org/10.1007/s40264-020-01010-6
Journal articles | 2019
Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR, 2019, 'Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease', European Journal of Clinical Pharmacology, 75, pp. 1481 - 1490, http://dx.doi.org/10.1007/s00228-019-02732-y
Journal articles | 2019
Milder TY; Stocker SL; Shaheed CA; McGrath-Cadell L; Samocha-Bonet D; Greenfield JR; Day RO, 2019, 'Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis', JOURNAL OF CLINICAL MEDICINE, 8, http://dx.doi.org/10.3390/jcm8010045
Milder DA; Milder TY; Kam PCA, 2018, 'Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations', Anaesthesia, 73, pp. 1008 - 1018, http://dx.doi.org/10.1111/anae.14251
Journal articles | 2011
Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514